Morbidly Obese are Ghrelin and Leptin Hyporesponders with Lesser Intragastric Balloon Treatment Efficiency
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Ghrelin and leptin recently emerged as the most influential neuroendocrine factors in the pathophysiology of obesity. The said peptides act in reciprocity and are responsible for regulation of appetite and energy metabolism. Intragastric balloons acquired worldwide popularity for obesity treatment. However, the roles of ghrelin and leptin in intragastric balloon treatment were still not systematically studied.
A prospective single-center study included 43 Caucasians treated with BioEnterics intragastric balloon, with age range of 18–60, and divided to non-morbid (body mass index cutoff 40 kg/m2) or morbid type of obesity, with 12 months follow-up. Serum hormonal samples were taken from fasting patients and kept frozen until analyses.
Significant differences were observed in anthropometrics and there were no differences between genders or comorbidities. The baseline weight for non-morbid vs. morbid was 104 kg (90–135) vs. 128.5 kg (104–197). Weight loss was statistically different between the studied groups during the study course with a median control weight at 6 months of 92 kg (72–121) vs. 107 kg (84–163), p < 0.001. Treatment was successful for 18 (94.7%) vs. 16 (66.7%) patients, p = 0.026. Ghrelin varied from 333.3 to 3,416.8 pg/ml and leptin from 1.7 to 61.2 ng/ml, with a statistically significant time-dependent relationship. A significant difference (p = 0.04) with emphasized ghrelin peak was found in the 3rd month of treatment for non-morbidly obese subjects.
The importance of ghrelin and leptin in treatment-induced changes was reaffirmed. Ghrelin hyper-response in non-morbidly obese subjects characterized greater short-term treatment efficiency and landmarked an inclination to weight regain. The results suggest a potential pattern of individualization between obese patients according to body mass index towards intragastric balloon or bariatric surgery. Further studies are needed in order to get better insights in the pathophysiologic mechanisms of obesity.
- Mathus-Vliegen EM. Obesity: intragastric balloons—a bubble to combat the obesity bubble? Nat Rev Gastroenterol Hepatol. 2010;7:7–8. CrossRef
- Dumonceau JM, Francois E, Hittelet A, et al. Single vs repeated treatment with the intragastric balloon: a 5-year weight loss study. Obes Surg. 2010;20:692–7. CrossRef
- Dastis NS, Francois E, Deviere J, et al. Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. Endoscopy. 2009;41:575–80. CrossRef
- Herve J, Wahlen CH, Schaeken A, et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg. 2005;15:864–70. CrossRef
- Dumonceau JM. Evidence-based review of the BioEnterics intragastric balloon for weight loss. Obes Surg. 2008;18:1611–7. CrossRef
- Tschop M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50:707–9. CrossRef
- Havel PJ. Peripheral signals conveying metabolic information to the brain: short-term and long-term regulation of food intake and energy homeostasis. Exp Biol Med (Maywood). 2001;226:963–77.
- Davis JF, Choi DL, Schurdak JD, et al. Leptin regulates energy balance and motivation through action at distinct neural circuits. Biol Psychiatry. 2010;69:668–74. CrossRef
- Mion F, Napoleon B, Roman S, et al. Effects of intragastric balloon on gastric emptying and plasma ghrelin levels in non-morbid obese patients. Obes Surg. 2005;15:510–6. CrossRef
- Konopko-Zubrzycka M, Baniukiewicz A, Wroblewski E, et al. The effect of intragastric balloon on plasma ghrelin, leptin, and adiponectin levels in patients with morbid obesity. J Clin Endocrinol Metab. 2009;94:1644–9. CrossRef
- Martinez-Brocca MA, Belda O, Parejo J, et al. Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity. Obes Surg. 2007;17:649–57. CrossRef
- Tymitz K, Engel A, McDonough S, et al. Changes in ghrelin levels following bariatric surgery: review of the literature. Obes Surg. 2011;21:125–30. CrossRef
- Tschop M, Wawarta R, Riepl RL, et al. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Investig. 2001;24:RC19–21.
- Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i–xii, 1–253.
- Favretti F, Mazrizio DL, Segato G, et al. The BioEnterics intragastric balloon for the nonsurgical treatment of obesity and morbid obesity. In: Schauer PR, Schirmer BD, Brethauer SA, et al., editors. Minimally invasive bariatric surgery. New York: Springer; 2007.
- Deitel M, Gawdat K, Melissas J. Reporting weight loss 2007. Obes Surg. 2007;17:565–8. CrossRef
- Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–60. CrossRef
- Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology. 2000;141:4255–61. CrossRef
- Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab. 2001;86:4753–8. CrossRef
- Sakata I, Nakamura K, Yamazaki M, et al. Ghrelin-producing cells exist as two types of cells, closed- and opened-type cells, in the rat gastrointestinal tract. Peptides. 2002;23:531–6. CrossRef
- Murray CD, Kamm MA, Bloom SR, et al. Ghrelin for the gastroenterologist: history and potential. Gastroenterology. 2003;125:1492–502. CrossRef
- Gualillo O, Caminos J, Blanco M, et al. Ghrelin, a novel placental-derived hormone. Endocrinology. 2001;142:788–94. CrossRef
- Drazen DL, Vahl TP, D’Alessio DA, et al. Effects of a fixed meal pattern on ghrelin secretion: evidence for a learned response independent of nutrient status. Endocrinology. 2006;147:23–30. CrossRef
- Faraj M, Havel PJ, Phelis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2003;88:1594–602. CrossRef
- Lopez-Nava G, Rubio MA, Prados S, et al. BioEnterics(R) intragastric balloon (BIB(R)). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg. 2011;21:5–9. CrossRef
- Genco A, Cipriano M, Bacci V, et al. Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: a prospective study on 100 patients. Obes Surg. 2010;20:1496–500. CrossRef
- Suzuki H, Hibi T. Does Helicobacter pylori attack ghrelin-producing cells? J Gastroenterol. 2005;40:437–9. CrossRef
- Fruhbeck G, Diez Caballero A, Gil MJ. Fundus functionality and ghrelin concentrations after bariatric surgery. N Engl J Med. 2004;350:308–9. CrossRef
- Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–32. CrossRef
- Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292–5. CrossRef
- Ahren B, Baldwin RM, Havel PJ. Pharmacokinetics of human leptin in mice and rhesus monkeys. Int J Obes Relat Metab Disord. 2000;24:1579–85. CrossRef
- Soderberg S, Ahren B, Jansson JH, et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med. 1999;246:409–18. CrossRef
- Soderberg S, Ahren B, Stegmayr B, et al. Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. Stroke. 1999;30:328–37. CrossRef
- Havel PJ. Role of adipose tissue in body-weight regulation: mechanisms regulating leptin production and energy balance. Proc Nutr Soc. 2000;59:359–71. CrossRef
- Levin N, Nelson C, Gurney A, et al. Decreased food intake does not completely account for adiposity reduction after ob protein infusion. Proc Natl Acad Sci USA. 1996;93:1726–30. CrossRef
- Licinio J, Caglayan S, Ozata M, et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci USA. 2004;101:4531–6. CrossRef
- Rosenbaum M, Goldsmith R, Bloomfield D, et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest. 2005;115:3579–86. CrossRef
- Nikolic M, Mirosevic G, Ljubicic N, et al. Obesity treatment using a BioEnterics intragastric balloon (BIB)—preliminary Croatian results. Obes Surg. 2010. doi:10.1007/s11695-010-0101-7.
- Sallet JA, Marchesini JB, Paiva DS, et al. Brazilian multicenter study of the intragastric balloon. Obes Surg. 2004;14:991–8. CrossRef
- Mathus-Vliegen EM. Intragastric balloon treatment for obesity: what does it really offer? Dig Dis. 2008;26:40–4. CrossRef
- Genco A, Cipriano M, Materia A, et al. Laparoscopic sleeve gastrectomy versus intragastric balloon: a case–control study. Surg Endosc. 2009;23:1849–53. CrossRef
- Melissas J, Mouzas J, Filis D, et al. The intragastric balloon—smoothing the path to bariatric surgery. Obes Surg. 2006;16:897–902. CrossRef
- Morbidly Obese are Ghrelin and Leptin Hyporesponders with Lesser Intragastric Balloon Treatment Efficiency
Volume 21, Issue 10 , pp 1597-1604
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- BIB-IB, BioEnterics intragastric balloon
- Non-morbid obesity
- Morbid obesity
- BMI, body mass index
- Treatment efficiency
- Treatment resistance
- Industry Sectors
- Author Affiliations
- 1. Interventional Gastroenterology Unit, Department of Internal Medicine, University Hospital Centre “Sestre Milosrdnice”, Vinogradska 29, Zagreb, 10000, Croatia
- 2. Department of Cardiovascular Diseases, University Hospital Centre “Rebro”, Zagreb, Croatia
- 3. Department of Clinical Biochemistry, University Hospital Centre “Sestre Milosrdnice”, Zagreb, Croatia
- 4. Department of Bariatric Surgery, University Hospital Centre “Sestre Milosrdnice”, Zagreb, Croatia